XNAS · Healthcare · Biotechnology
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.11 | -0.10 | +9.09% | $15.2M | ✅ Beat | -0.76% | -0.39% | — |
| 2026-03-11 | Q4 2025 | -0.04 | 0.11 | +375.00% | $38.9M | ✅ Beat | +37.80% | +15.75% | +76.38% |
| 2025-11-06 |
| Q3 2025 |
| -0.14 |
| -0.22 |
| -57.14% |
| $8.6M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.16 | -0.16 | +200.00% | $15.3M | mixed | +3.23% | -7.54% | -20.33% |
| 2025-02-27 | Q4 2024 | -0.02 | -0.13 | -550.00% | $21.5M | ❌ Miss | -22.65% | -30.53% | -31.55% |
| 2024-10-31 | Q3 2024 | -0.24 | -0.29 | -20.83% | $12.8M | ❌ Miss | +11.46% | +33.12% | +50.32% |
| 2024-08-08 | Q2 2024 | -0.27 | -0.32 | -18.52% | $8.0M | ❌ Miss | -11.11% | -10.79% | -16.83% |
| 2024-05-02 | Q1 2024 | -0.18 | -0.16 | +11.11% | $17.1M | ✅ Beat | +17.37% | +3.89% | +4.19% |
Showing last 8 quarters.